Indacaterol on dyspnea in chronic obstructive pulmonary disease: a systematic review and meta-analysis of randomized placebo-controlled trials

BACKGROUND: Indacaterol is a novel, once-daily (od), inhaled, long-acting ß(2)-agonist bronchodilator for maintenance treatment of airflow limitation in patients with COPD. The aim of this study was to evaluate the efficacy of indacaterol on dyspnea, using available randomized placebo-controlled tri...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Jiangna, Dai, Lu, Zhong, Nanshan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3651265/
https://www.ncbi.nlm.nih.gov/pubmed/23617268
http://dx.doi.org/10.1186/1471-2466-13-26

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3651265/
https://www.ncbi.nlm.nih.gov/pubmed/23617268
http://dx.doi.org/10.1186/1471-2466-13-26

Ejemplares similares